Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients
Trial ID or NCT#
Status
Purpose
Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya disease and stroke patients
Official Title
Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients
Eligibility Criteria
- Moyamoya Patient Inclusion Criteria: - Men and non-pregnant women, at least 21 years of age. - Outpatients seen at the Stanford Neurosurgery and Neurology Departments. - Ability to comply with all studies. - Inclusion of Moyamoya patients with Sulfa allergies. - Patients diagnosed with or suspected to have Moyamoya disease. Stroke Patient Inclusion Criteria: - Men and non-pregnant women, at least 21 years of age. - Patients admitted to the inpatient Stanford Stroke Service for stroke-like symptoms, less than 24 hours from last time seen normal. - Ability to comply with all studies. Clinical Patient Acetazolamide MRI Inclusion Criteria: - Men and non-pregnant women, at least 21 years of age. - Patients admitted to the inpatient Stanford Stroke Service or Neurosurgical -Service for symptoms compatible with cerebrovascular disease. - Ability to comply with all studies. Normal Subject Inclusion Criteria: - Ability to comply with the MRI study.
- - Level of consciousness score of 2 or greater as defined by the NIH stroke scale. - Symptoms likely related to psychoactive drugs or patients with symptoms related to an active inflammatory disease such as AIDS, meningitis, or cerebritis. - Psychiatric or substance abuse disorder or dementia that interferes with evaluation or interpretation of the neurologic and mental assessment of these patients. - Informed consent cannot be obtained either from the patient or legal representative. - Severe coexisting or terminal systemic disease that limits life expectancy or that may interfere with the conduct of the study. - Symptoms related to an alternative diagnosis such as seizures or migraine. - Patients receiving any thrombolytic agent or receiving acute stroke investigational drug therapies during the 30-day study.
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Sandra Dunn
650-724-8278
View on ClinicalTrials.gov